474 related articles for article (PubMed ID: 22130620)
1. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
2. Individualized surgical strategies for cancer of the esophagogastric junction.
Stein HJ; Feith M; Siewert JR
Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
[TBL] [Abstract][Full Text] [Related]
3. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
4. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
7. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
8. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?
Gertler R; Stein HJ; Loos M; Langer R; Friess H; Feith M
Am J Surg Pathol; 2011 Oct; 35(10):1512-22. PubMed ID: 21934477
[TBL] [Abstract][Full Text] [Related]
9. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
10. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
12. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.
von Rahden BH; Stein HJ; Feith M; Becker K; Siewert JR
J Clin Oncol; 2005 Feb; 23(4):874-9. PubMed ID: 15681533
[TBL] [Abstract][Full Text] [Related]
13. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
15. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
16. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
[TBL] [Abstract][Full Text] [Related]
17. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
18. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
20. Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma.
Hosoda K; Yamashita K; Katada N; Moriya H; Mieno H; Sakuramoto S; Kikuchi S; Watanabe M
Anticancer Res; 2015 Jan; 35(1):419-25. PubMed ID: 25550582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]